F. Hafezi, M. Hillen, L. Kollros, Nikki L. Hafezi, E. A. Torres-Netto
{"title":"Corneal Cross-linking in Thin Corneas: From Origins to State of the Art","authors":"F. Hafezi, M. Hillen, L. Kollros, Nikki L. Hafezi, E. A. Torres-Netto","doi":"10.17925/usor.2022.16.1.13","DOIUrl":null,"url":null,"abstract":"Corneal cross-linking (CXL) can halt ectasia progression and involves saturating the stroma with riboflavin, followed by ultraviolet-A (UV-A) light irradiation. This generates reactive oxygen species that covalently cross-link together stromal molecules, strengthening the cornea. The ‘Dresden protocol’ left a 70 µm uncross-linked region at the base of the stroma to protect the corneal endothelium from UV damage; however, this limited CXL to corneas ≥400 µm. Approaches made to overcome this limitation involved artificial corneal thickening to ≥400 μm through swelling the stroma with hypo-osmolaric riboflavin, applying riboflavin-soaked contact lenses during UV irradiation or leaving ‘epithelial islands’ over the thinnest corneal regions. The drawbacks to these three approaches are unpredictable swelling, suboptimal stiffening and unpredictable cross-linking effects, respectively. Newer approaches adapt the irradiation protocol to the cornea to deliver CXL that maintains the 70 μm uncross-linked stroma safety margin. The sub400 protocol employs an algorithm that models the interactions between UV-A energy, riboflavin, oxygen diffusion and stromal thickness. It requires only corneal pachymetry measurements at the thinnest point and the selection of the appropriate UV irradiation time from a look-up table to cross-link corneas as thin as 200 µm safely and effectively.","PeriodicalId":90077,"journal":{"name":"US ophthalmic review","volume":"77 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"US ophthalmic review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17925/usor.2022.16.1.13","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Corneal cross-linking (CXL) can halt ectasia progression and involves saturating the stroma with riboflavin, followed by ultraviolet-A (UV-A) light irradiation. This generates reactive oxygen species that covalently cross-link together stromal molecules, strengthening the cornea. The ‘Dresden protocol’ left a 70 µm uncross-linked region at the base of the stroma to protect the corneal endothelium from UV damage; however, this limited CXL to corneas ≥400 µm. Approaches made to overcome this limitation involved artificial corneal thickening to ≥400 μm through swelling the stroma with hypo-osmolaric riboflavin, applying riboflavin-soaked contact lenses during UV irradiation or leaving ‘epithelial islands’ over the thinnest corneal regions. The drawbacks to these three approaches are unpredictable swelling, suboptimal stiffening and unpredictable cross-linking effects, respectively. Newer approaches adapt the irradiation protocol to the cornea to deliver CXL that maintains the 70 μm uncross-linked stroma safety margin. The sub400 protocol employs an algorithm that models the interactions between UV-A energy, riboflavin, oxygen diffusion and stromal thickness. It requires only corneal pachymetry measurements at the thinnest point and the selection of the appropriate UV irradiation time from a look-up table to cross-link corneas as thin as 200 µm safely and effectively.